• |
  • |
  • |
  • |
Donate

Product

Journal: Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome

Center:
Fiscal Year:
2026
Contact Information:
Product Description:
Interim analysis results of the ongoing OLE in children, adolescents, and young adults with FXS demonstrated that ZYN002 has a favorable long-term safety profile and is generally well tolerated. Clinically meaningful changes in behaviors from baseline continued to be observed during the OLE. These findings support further study of ZYN002 in patients with FXS.
Keyword(s):
Endocannabinoid system, Fragile x syndrome, Irritability; Social avoidance, Transdermal cannabidiol
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals
Alternative Format:
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A